You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBivalirudin
Accession NumberDB00006  (BTD00076, BIOD00076)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionBivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and blood pressure.
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AngiomaxInjection, powder, lyophilized, for solution250 mg/1IntravenousCardinal Health2000-12-15Not applicableUs
AngiomaxInjection, powder, lyophilized, for solution250 mg/1IntravenousThe Medicines Company2000-12-15Not applicableUs
AngiomaxPowder, for solution250 mgIntravenousSandoz Canada Incorporated2003-05-08Not applicableCanada
BivalirudinInjection, powder, lyophilized, for solution250 mg/1IntravenousSandoz2015-06-15Not applicableUs
BivalirudinInjection, powder, lyophilized, for solution250 mg/1IntravenousSandoz2015-10-23Not applicableUs
BivalirudinPowder, for solution250 mgIntravenousSandoz Canada IncorporatedNot applicableNot applicableCanada
Bivalirudin for InjectionPowder, for solution250 mgIntravenousFresenius Kabi Canada LtdNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BivalirudinInjection, powder, lyophilized, for solution250 mg/1IntravenousHospira, Inc.2015-07-14Not applicableUs
BivalirudinInjection, powder, lyophilized, for solution250 mg/1IntravenousSagent Pharmaceuticals2016-10-01Not applicableUs
BivalirudinInjection, powder, lyophilized, for solution250 mg/1IntravenousFresenius Kabi USA, LLC2016-06-08Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AngioxNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIITN9BEX005G
CAS number128270-60-0
WeightAverage: 2180.2853
Monoisotopic: 2178.985813062
Chemical FormulaC98H138N24O33
InChI KeyOIRCOABEOLEUMC-GEJPAHFPSA-N
InChI
InChI=1S/C98H138N24O33/c1-5-52(4)82(96(153)122-39-15-23-70(122)92(149)114-60(30-34-79(134)135)85(142)111-59(29-33-78(132)133)86(143)116-64(43-55-24-26-56(123)27-25-55)89(146)118-67(97(154)155)40-51(2)3)119-87(144)61(31-35-80(136)137)112-84(141)58(28-32-77(130)131)113-88(145)63(42-54-18-10-7-11-19-54)117-90(147)66(45-81(138)139)110-76(129)50-107-83(140)65(44-71(100)124)109-75(128)49-106-73(126)47-104-72(125)46-105-74(127)48-108-91(148)68-21-13-38-121(68)95(152)62(20-12-36-103-98(101)102)115-93(150)69-22-14-37-120(69)94(151)57(99)41-53-16-8-6-9-17-53/h6-11,16-19,24-27,51-52,57-70,82,123H,5,12-15,20-23,28-50,99H2,1-4H3,(H2,100,124)(H,104,125)(H,105,127)(H,106,126)(H,107,140)(H,108,148)(H,109,128)(H,110,129)(H,111,142)(H,112,141)(H,113,145)(H,114,149)(H,115,150)(H,116,143)(H,117,147)(H,118,146)(H,119,144)(H,130,131)(H,132,133)(H,134,135)(H,136,137)(H,138,139)(H,154,155)(H4,101,102,103)/t52-,57+,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,82-/m0/s1
IUPAC Name
(4S)-4-[(2S)-2-[(2S)-2-[(2S)-2-{2-[(2S)-2-(2-{2-[2-(2-{[(2S)-1-[(2S)-2-{[(2S)-1-[(2R)-2-amino-3-phenylpropanoyl]pyrrolidin-2-yl]formamido}-5-carbamimidamidopentanoyl]pyrrolidin-2-yl]formamido}acetamido)acetamido]acetamido}acetamido)-3-carbamoylpropanamido]acetamido}-3-carboxypropanamido]-3-phenylpropanamido]-4-carboxybutanamido]-4-{[(2S,3S)-1-[(2S)-2-{[(1S)-3-carboxy-1-{[(1S)-3-carboxy-1-{[(1S)-1-{[(1S)-1-carboxy-3-methylbutyl]carbamoyl}-2-(4-hydroxyphenyl)ethyl]carbamoyl}propyl]carbamoyl}propyl]carbamoyl}pyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]carbamoyl}butanoic acid
SMILES
CC[[email protected]](C)[[email protected]](NC(=O)[[email protected]](CCC(O)=O)NC(=O)[[email protected]](CCC(O)=O)NC(=O)[[email protected]](CC1=CC=CC=C1)NC(=O)[[email protected]](CC(O)=O)NC(=O)CNC(=O)[[email protected]](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[[email protected]](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[[email protected]](N)CC1=CC=CC=C1)C(=O)N1CCC[[email protected]]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O
Pharmacology
IndicationFor treatment of heparin-induced thrombocytopenia and for the prevention of thrombosis. Bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention (PCI), in patients at moderate to high risk acute coronary syndromes due to unstable angina or non-ST segment elevation in whom a PCI is planned.
Structured Indications
PharmacodynamicsBivalirudin directly and reversibly inhibits thrombin by specifically binding both to the catalytic site and to the anion-binding exosite of circulating and clot-bound thrombin. The action of bivalirudin is reversible because thrombin will slowly cleave the thrombin-bivalirudin bond which recovers the active site of thrombin.
Mechanism of actionInhibits the action of thrombin by binding both to its catalytic site and to its anion-binding exosite. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked framework which stabilizes the thrombus; thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release.
TargetKindPharmacological actionActionsOrganismUniProt ID
ProthrombinProteinyes
inhibitor
HumanP00734 details
Related Articles
AbsorptionFollowing intravenous administration, bivalirudin exhibits linear pharmacokinetics . The mean steady state concentration is 12.3 +/- 1.7mcg/mL after administration of an intravenous bolus of 1mg/kg followd by a 2.5mg/kg/hr intravenous infusion given over 4 hours.
Volume of distribution

0.2L/kg

Protein bindingOther than thrombin and red blood cells, bivalirudin does not bind to plasma proteins.
Metabolism

80% proteolytic cleavage

Route of eliminationBivalirudin is cleared from plasma by a combination of renal mechanisms (20%) and proteolytic cleavage.
Half life* Normal renal function: 25 min (in normal conditions) * Creatinine clearance 10-29mL/min: 57min * Dialysis-dependant patients: 3.5h
Clearance
  • 3.4 mL/min/kg [Normal renal function]
  • 3.4 mL/min/kg [mild renal function]
  • 2.7 mL/min/kg [moderate renal function]
  • 2.8 mL/min/kg [severe renal function]
  • 1 mL/min/kg [Dialysis-dependent patients]
ToxicityBased on a study by Gleason et al., the no-observed-adverse-effect level (NOAEL) for bivalirudin, administered to rats via intravenous infusion over a 24-hour period, was 2000 mg/kg/24 h.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Bivalirudin Action PathwayDrug actionSMP00277
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Bivalirudin.Approved, Investigational
AbciximabBivalirudin may increase the anticoagulant activities of Abciximab.Approved
AceclofenacAceclofenac may increase the anticoagulant activities of Bivalirudin.Approved
AcenocoumarolBivalirudin may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneAcetovanillone may increase the anticoagulant activities of Bivalirudin.Investigational
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Bivalirudin.Approved, Vet Approved
AdapaleneAdapalene may increase the anticoagulant activities of Bivalirudin.Approved
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Bivalirudin.Approved, Investigational
AllylestrenolThe therapeutic efficacy of Bivalirudin can be decreased when used in combination with Allylestrenol.Approved
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Bivalirudin.Approved, Illicit, Investigational
AlprostadilAlprostadil may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Bivalirudin.Approved
AltrenogestThe therapeutic efficacy of Bivalirudin can be decreased when used in combination with Altrenogest.Vet Approved
ALX-0081ALX-0081 may increase the anticoagulant activities of Bivalirudin.Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Bivalirudin.Experimental
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Bivalirudin.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Bivalirudin.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Bivalirudin.Approved
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Bivalirudin.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Bivalirudin.Approved
AncrodBivalirudin may increase the anticoagulant activities of Ancrod.Investigational
AnisodamineAnisodamine may increase the anticoagulant activities of Bivalirudin.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Bivalirudin.Approved
AntipyrineAntipyrine may increase the anticoagulant activities of Bivalirudin.Approved
Antithrombin III humanBivalirudin may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanApixaban may increase the anticoagulant activities of Bivalirudin.Approved
ApremilastApremilast may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
AprotininThe therapeutic efficacy of Bivalirudin can be decreased when used in combination with Aprotinin.Approved, Withdrawn
ArdeparinBivalirudin may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanBivalirudin may increase the anticoagulant activities of Argatroban.Approved, Investigational
AstaxanthinAstaxanthin may increase the anticoagulant activities of Bivalirudin.Investigational
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Bivalirudin.Approved
AzapropazoneAzapropazone may increase the anticoagulant activities of Bivalirudin.Withdrawn
AzelastineAzelastine may increase the anticoagulant activities of Bivalirudin.Approved
BalsalazideBalsalazide may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BatroxobinBatroxobin may increase the anticoagulant activities of Bivalirudin.Experimental
BazedoxifeneBazedoxifene may decrease the anticoagulant activities of Bivalirudin.Approved, Investigational
BecaplerminBivalirudin may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BemiparinBemiparin may increase the anticoagulant activities of Bivalirudin.Approved
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Bivalirudin.Withdrawn
BeraprostBeraprost may increase the anticoagulant activities of Bivalirudin.Investigational
Betulinic AcidBetulinic Acid may increase the anticoagulant activities of Bivalirudin.Investigational
BoceprevirThe serum concentration of Bivalirudin can be decreased when it is combined with Boceprevir.Approved
BromfenacBromfenac may increase the anticoagulant activities of Bivalirudin.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Bivalirudin.Approved, Investigational
BucillamineBucillamine may increase the anticoagulant activities of Bivalirudin.Investigational
ButylphthalideButylphthalide may increase the anticoagulant activities of Bivalirudin.Investigational
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Bivalirudin.Approved
CangrelorCangrelor may increase the anticoagulant activities of Bivalirudin.Approved
CarbamazepineThe metabolism of Bivalirudin can be increased when combined with Carbamazepine.Approved, Investigational
CarprofenCarprofen may increase the anticoagulant activities of Bivalirudin.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may increase the anticoagulant activities of Bivalirudin.Experimental
CelecoxibCelecoxib may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
CertoparinBivalirudin may increase the anticoagulant activities of Certoparin.Approved
ChloroquineChloroquine may increase the anticoagulant activities of Bivalirudin.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Bivalirudin.Withdrawn
CilostazolCilostazol may increase the anticoagulant activities of Bivalirudin.Approved
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Bivalirudin.Approved, Investigational, Withdrawn
Citric AcidBivalirudin may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Bivalirudin.Approved
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Bivalirudin.Approved, Vet Approved
ClonixinClonixin may increase the anticoagulant activities of Bivalirudin.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Bivalirudin.Approved, Nutraceutical
CollagenaseThe risk or severity of adverse effects can be increased when Bivalirudin is combined with Collagenase.Approved
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Bivalirudin.Approved
CurcuminCurcumin may increase the anticoagulant activities of Bivalirudin.Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Bivalirudin.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Bivalirudin is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Bivalirudin.Approved, Investigational, Vet Approved
D-LimoneneD-Limonene may increase the anticoagulant activities of Bivalirudin.Investigational
Dabigatran etexilateDabigatran etexilate may increase the anticoagulant activities of Bivalirudin.Approved
DalteparinBivalirudin may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidBivalirudin may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DasatinibDasatinib may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Bivalirudin is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Bivalirudin.Approved
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Bivalirudin is combined with Deoxycholic Acid.Approved
dersalazinedersalazine may increase the anticoagulant activities of Bivalirudin.Investigational
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Bivalirudin.Approved
DesirudinBivalirudin may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Bivalirudin.Investigational
DesogestrelThe therapeutic efficacy of Bivalirudin can be decreased when used in combination with Desogestrel.Approved
DextranBivalirudin may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Bivalirudin may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Bivalirudin may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Bivalirudin may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacDiclofenac may increase the anticoagulant activities of Bivalirudin.Approved, Vet Approved
DicoumarolBivalirudin may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Bivalirudin.Approved
DienogestThe therapeutic efficacy of Bivalirudin can be decreased when used in combination with Dienogest.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Bivalirudin.Approved
DiflunisalDiflunisal may increase the anticoagulant activities of Bivalirudin.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Bivalirudin.Approved
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Bivalirudin.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Bivalirudin.Approved
DipyridamoleDipyridamole may increase the anticoagulant activities of Bivalirudin.Approved
DitazoleDitazole may increase the anticoagulant activities of Bivalirudin.Approved, Withdrawn
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Bivalirudin.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Bivalirudin.Approved
DrospirenoneThe therapeutic efficacy of Bivalirudin can be decreased when used in combination with Drospirenone.Approved
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Bivalirudin.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the anticoagulant activities of Bivalirudin.Approved
DuvelisibDuvelisib may increase the anticoagulant activities of Bivalirudin.Investigational
DydrogesteroneThe therapeutic efficacy of Bivalirudin can be decreased when used in combination with Dydrogesterone.Approved, Withdrawn
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Bivalirudin.Approved
E6201E6201 may increase the anticoagulant activities of Bivalirudin.Investigational
EbselenEbselen may increase the anticoagulant activities of Bivalirudin.Investigational
Edetic AcidBivalirudin may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanEdoxaban may increase the anticoagulant activities of Bivalirudin.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Bivalirudin.Approved, Investigational
EnoxaparinBivalirudin may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineEpinastine may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
EpirizoleEpirizole may increase the anticoagulant activities of Bivalirudin.Approved
eplivanserineeplivanserine may increase the anticoagulant activities of Bivalirudin.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Bivalirudin.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Bivalirudin.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Bivalirudin.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Bivalirudin.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Bivalirudin.Investigational
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Bivalirudin.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Bivalirudin.Approved
EstriolEstriol may decrease the anticoagulant activities of Bivalirudin.Approved, Vet Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Bivalirudin.Approved
EstroneEstrone may decrease the anticoagulant activities of Bivalirudin.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Bivalirudin.Approved
EtanerceptEtanercept may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Bivalirudin.Approved
Ethyl biscoumacetateBivalirudin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethynodiol diacetateThe therapeutic efficacy of Bivalirudin can be decreased when used in combination with Ethynodiol diacetate.Approved
EtodolacEtodolac may increase the anticoagulant activities of Bivalirudin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Bivalirudin.Approved
EtonogestrelThe therapeutic efficacy of Bivalirudin can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoricoxibEtoricoxib may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Bivalirudin.Approved
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Bivalirudin.Approved
exisulindexisulind may increase the anticoagulant activities of Bivalirudin.Investigational
FenbufenFenbufen may increase the anticoagulant activities of Bivalirudin.Approved
FenoprofenFenoprofen may increase the anticoagulant activities of Bivalirudin.Approved
FibrinolysinFibrinolysin may increase the anticoagulant activities of Bivalirudin.Approved
FloctafenineFloctafenine may increase the anticoagulant activities of Bivalirudin.Approved, Withdrawn
FluindioneBivalirudin may increase the anticoagulant activities of Fluindione.Investigational
FlunixinFlunixin may increase the anticoagulant activities of Bivalirudin.Vet Approved
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
FondaparinuxBivalirudin may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumBivalirudin may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
GabexateBivalirudin may increase the anticoagulant activities of Gabexate.Investigational
GarlicThe serum concentration of Bivalirudin can be decreased when it is combined with Garlic.Approved
GenisteinGenistein may decrease the anticoagulant activities of Bivalirudin.Investigational
GestodeneThe therapeutic efficacy of Bivalirudin can be decreased when used in combination with Gestodene.Approved
GestrinoneThe therapeutic efficacy of Bivalirudin can be decreased when used in combination with Gestrinone.Approved
HeminHemin may increase the anticoagulant activities of Bivalirudin.Approved
HeparinBivalirudin may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Bivalirudin.Withdrawn
HigenamineHigenamine may increase the anticoagulant activities of Bivalirudin.Investigational
HirulogBivalirudin may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004HMPL-004 may increase the anticoagulant activities of Bivalirudin.Investigational
Hydroxyprogesterone caproateThe therapeutic efficacy of Bivalirudin can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Bivalirudin is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Bivalirudin.Approved
IbudilastIbudilast may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
IbuprofenIbuprofen may increase the anticoagulant activities of Bivalirudin.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Bivalirudin.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Bivalirudin.Approved
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Bivalirudin.Approved, Nutraceutical
idraparinuxBivalirudin may increase the anticoagulant activities of idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Bivalirudin.Approved, Withdrawn
IloprostIloprost may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Bivalirudin.Approved
IndobufenIndobufen may increase the anticoagulant activities of Bivalirudin.Investigational
IndomethacinIndomethacin may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Bivalirudin.Withdrawn
IsoxicamIsoxicam may increase the anticoagulant activities of Bivalirudin.Withdrawn
Kct 0809Kct 0809 may increase the anticoagulant activities of Bivalirudin.Investigational
KebuzoneKebuzone may increase the anticoagulant activities of Bivalirudin.Experimental
KetanserinKetanserin may increase the anticoagulant activities of Bivalirudin.Investigational
KetoprofenKetoprofen may increase the anticoagulant activities of Bivalirudin.Approved, Vet Approved
KetorolacKetorolac may increase the anticoagulant activities of Bivalirudin.Approved
LeflunomideLeflunomide may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
LepirudinLepirudin may increase the anticoagulant activities of Bivalirudin.Approved
LevonorgestrelThe therapeutic efficacy of Bivalirudin can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Bivalirudin.Approved
LisofyllineLisofylline may increase the anticoagulant activities of Bivalirudin.Investigational
LornoxicamLornoxicam may increase the anticoagulant activities of Bivalirudin.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Bivalirudin.Approved, Investigational
LoxoprofenLoxoprofen may increase the anticoagulant activities of Bivalirudin.Approved
LumiracoxibLumiracoxib may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
LynestrenolThe therapeutic efficacy of Bivalirudin can be decreased when used in combination with Lynestrenol.Investigational
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Bivalirudin.Approved
MasoprocolMasoprocol may increase the anticoagulant activities of Bivalirudin.Approved
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Bivalirudin.Approved, Vet Approved
MedrogestoneThe therapeutic efficacy of Bivalirudin can be decreased when used in combination with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Bivalirudin can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Bivalirudin.Approved
Megestrol acetateThe therapeutic efficacy of Bivalirudin can be decreased when used in combination with Megestrol acetate.Approved, Vet Approved
MeloxicamMeloxicam may increase the anticoagulant activities of Bivalirudin.Approved, Vet Approved
MesalazineMesalazine may increase the anticoagulant activities of Bivalirudin.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Bivalirudin.Approved
MetamizoleMetamizole may increase the anticoagulant activities of Bivalirudin.Withdrawn
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Bivalirudin.Experimental
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Bivalirudin.Approved, Illicit
MilrinoneMilrinone may increase the anticoagulant activities of Bivalirudin.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Bivalirudin.Approved
MizoribineMizoribine may increase the anticoagulant activities of Bivalirudin.Investigational
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Bivalirudin.Approved
NabumetoneNabumetone may increase the anticoagulant activities of Bivalirudin.Approved
NadroparinBivalirudin may increase the anticoagulant activities of Nadroparin.Approved
NafamostatNafamostat may increase the anticoagulant activities of Bivalirudin.Investigational
NaftifineNaftifine may increase the anticoagulant activities of Bivalirudin.Approved
NaftopidilNaftopidil may increase the anticoagulant activities of Bivalirudin.Investigational
NaproxenNaproxen may increase the anticoagulant activities of Bivalirudin.Approved, Vet Approved
NCX 4016NCX 4016 may increase the anticoagulant activities of Bivalirudin.Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Bivalirudin.Approved, Withdrawn
NepafenacNepafenac may increase the anticoagulant activities of Bivalirudin.Approved
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Bivalirudin.Approved
NimesulideNimesulide may increase the anticoagulant activities of Bivalirudin.Approved, Withdrawn
NintedanibThe risk or severity of adverse effects can be increased when Bivalirudin is combined with Nintedanib.Approved
NitroaspirinNitroaspirin may increase the anticoagulant activities of Bivalirudin.Investigational
NomegestrolThe therapeutic efficacy of Bivalirudin can be decreased when used in combination with Nomegestrol.Approved
NorethisteroneThe therapeutic efficacy of Bivalirudin can be decreased when used in combination with Norethisterone.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Bivalirudin.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Bivalirudin is combined with Obinutuzumab.Approved
OlopatadineOlopatadine may increase the anticoagulant activities of Bivalirudin.Approved
OlsalazineOlsalazine may increase the anticoagulant activities of Bivalirudin.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Bivalirudin is combined with Omacetaxine mepesuccinate.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Bivalirudin.Approved
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Bivalirudin.Investigational
OrgoteinOrgotein may increase the anticoagulant activities of Bivalirudin.Vet Approved
OtamixabanBivalirudin may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinOxaprozin may increase the anticoagulant activities of Bivalirudin.Approved
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Bivalirudin.Withdrawn
ParecoxibParecoxib may increase the anticoagulant activities of Bivalirudin.Approved
ParnaparinParnaparin may increase the anticoagulant activities of Bivalirudin.Approved
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Bivalirudin.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
PethidineThe risk or severity of adverse effects can be increased when Bivalirudin is combined with Pethidine.Approved
PhenindioneBivalirudin may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonBivalirudin may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Bivalirudin.Approved, Vet Approved
PimecrolimusPimecrolimus may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Bivalirudin.Approved
PirfenidonePirfenidone may increase the anticoagulant activities of Bivalirudin.Investigational
PiroxicamPiroxicam may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
PlasminPlasmin may increase the anticoagulant activities of Bivalirudin.Investigational
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Bivalirudin.Approved
PrasugrelPrasugrel may increase the anticoagulant activities of Bivalirudin.Approved
ProgesteroneThe therapeutic efficacy of Bivalirudin can be decreased when used in combination with Progesterone.Approved, Vet Approved
PromestrienePromestriene may decrease the anticoagulant activities of Bivalirudin.Investigational
PropacetamolPropacetamol may increase the anticoagulant activities of Bivalirudin.Approved
Protein CBivalirudin may increase the anticoagulant activities of Protein C.Approved
Protein S humanBivalirudin may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeBivalirudin may increase the anticoagulant activities of Protocatechualdehyde.Approved
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Bivalirudin.Approved
PTC299PTC299 may increase the anticoagulant activities of Bivalirudin.Investigational
QuinestrolQuinestrol may decrease the anticoagulant activities of Bivalirudin.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Bivalirudin.Investigational
ResveratrolResveratrol may increase the anticoagulant activities of Bivalirudin.Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Bivalirudin.Approved
ReviparinBivalirudin may increase the anticoagulant activities of Reviparin.Approved
RidogrelRidogrel may increase the anticoagulant activities of Bivalirudin.Approved
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Bivalirudin.Approved
RivaroxabanBivalirudin may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the anticoagulant activities of Bivalirudin.Investigational, Withdrawn
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Bivalirudin.Approved
S EquolS Equol may decrease the anticoagulant activities of Bivalirudin.Investigational
SalicylamideSalicylamide may increase the anticoagulant activities of Bivalirudin.Approved
Salicylic acidSalicylic acid may increase the anticoagulant activities of Bivalirudin.Approved, Vet Approved
SalsalateSalsalate may increase the anticoagulant activities of Bivalirudin.Approved
SCH-530348SCH-530348 may increase the anticoagulant activities of Bivalirudin.Investigational
SecoisolariciresinolSecoisolariciresinol may decrease the anticoagulant activities of Bivalirudin.Investigational
SelexipagSelexipag may increase the anticoagulant activities of Bivalirudin.Approved
SeratrodastSeratrodast may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
SevofluraneSevoflurane may increase the anticoagulant activities of Bivalirudin.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Bivalirudin.Approved, Investigational
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Bivalirudin.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Bivalirudin.Approved
SRT501SRT501 may increase the anticoagulant activities of Bivalirudin.Investigational
St. John's WortThe metabolism of Bivalirudin can be increased when combined with St. John's Wort.Nutraceutical
StreptokinaseStreptokinase may increase the anticoagulant activities of Bivalirudin.Approved
SugammadexSugammadex may increase the anticoagulant activities of Bivalirudin.Approved
SulfasalazineSulfasalazine may increase the anticoagulant activities of Bivalirudin.Approved
SulindacSulindac may increase the anticoagulant activities of Bivalirudin.Approved
SulodexideBivalirudin may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SuprofenSuprofen may increase the anticoagulant activities of Bivalirudin.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Bivalirudin.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Bivalirudin.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Bivalirudin.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Bivalirudin is combined with Temsirolimus.Approved
TenecteplaseTenecteplase may increase the anticoagulant activities of Bivalirudin.Approved
TenoxicamTenoxicam may increase the anticoagulant activities of Bivalirudin.Approved
TepoxalinTepoxalin may increase the anticoagulant activities of Bivalirudin.Vet Approved
TeriflunomideTeriflunomide may increase the anticoagulant activities of Bivalirudin.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Bivalirudin.Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Bivalirudin.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Bivalirudin.Approved
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Bivalirudin.Approved
TiboloneTibolone may increase the anticoagulant activities of Bivalirudin.Approved
TicagrelorTicagrelor may increase the anticoagulant activities of Bivalirudin.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Bivalirudin.Approved
TinoridineTinoridine may increase the anticoagulant activities of Bivalirudin.Investigational
TinzaparinTinzaparin may increase the anticoagulant activities of Bivalirudin.Approved
TipranavirThe serum concentration of Bivalirudin can be decreased when it is combined with Tipranavir.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Bivalirudin.Approved
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Bivalirudin.Approved
TolmetinTolmetin may increase the anticoagulant activities of Bivalirudin.Approved
TositumomabThe risk or severity of adverse effects can be increased when Bivalirudin is combined with Tositumomab.Approved
TranilastTranilast may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Bivalirudin.Approved
TreprostinilTreprostinil may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Bivalirudin.Approved
TriflusalTriflusal may increase the anticoagulant activities of Bivalirudin.Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Bivalirudin.Approved
Trisalicylate-cholineTrisalicylate-choline may increase the anticoagulant activities of Bivalirudin.Approved
UrokinaseUrokinase may increase the anticoagulant activities of Bivalirudin.Approved, Investigational, Withdrawn
ValdecoxibValdecoxib may increase the anticoagulant activities of Bivalirudin.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Bivalirudin.Approved, Investigational
VerapamilThe metabolism of Verapamil can be decreased when combined with Bivalirudin.Approved
Vitamin EVitamin E may increase the anticoagulant activities of Bivalirudin.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Bivalirudin.Approved
WarfarinBivalirudin may increase the anticoagulant activities of Warfarin.Approved
XimelagatranBivalirudin may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Bivalirudin may increase the anticoagulant activities of Ym150.Investigational
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Bivalirudin.Approved
ZeranolZeranol may decrease the anticoagulant activities of Bivalirudin.Vet Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Bivalirudin.Approved
ZileutonZileuton may increase the anticoagulant activities of Bivalirudin.Approved, Investigational, Withdrawn
ZomepiracZomepirac may increase the anticoagulant activities of Bivalirudin.Withdrawn
Food Interactions
  • Dan shen, dong quai, evening primrose oil, gingko, policosanol, willow bark
  • Echinacea
References
Synthesis Reference

Avi Tovi, Chaim Eidelman, Shimon Shushan, Alon Hagi, Alexander Ivchenko, Gabriel-Marcus Butilca, Leah Bar-Oz, Tehila Gadi, Gil Zaovi, “Process for production of Bivalirudin.” U.S. Patent US20070093423, issued April 26, 2007.

US20070093423
General References
  1. Seybert AL, Coons JC, Zerumsky K: Treatment of heparin-induced thrombocytopenia: is there a role for bivalirudin? Pharmacotherapy. 2006 Feb;26(2):229-41. [PubMed:16466327 ]
  2. Dager WE, Dougherty JA, Nguyen PH, Militello MA, Smythe MA: Heparin-induced thrombocytopenia: treatment options and special considerations. Pharmacotherapy. 2007 Apr;27(4):564-87. [PubMed:17381384 ]
  3. Dang CH, Durkalski VL, Nappi JM: Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia. Pharmacotherapy. 2006 Apr;26(4):461-8. [PubMed:16553503 ]
  4. Robson R: The use of bivalirudin in patients with renal impairment. J Invasive Cardiol. 2000 Dec;12 Suppl F:33F-6. [PubMed:11156732 ]
  5. Van De Car DA, Rao SV, Ohman EM: Bivalirudin: a review of the pharmacology and clinical application. Expert Rev Cardiovasc Ther. 2010 Dec;8(12):1673-81. doi: 10.1586/erc.10.158. [PubMed:21108549 ]
  6. Shammas NW: Bivalirudin: pharmacology and clinical applications. Cardiovasc Drug Rev. 2005 Winter;23(4):345-60. [PubMed:16614733 ]
  7. Gleason TG, Chengelis CP, Jackson CB, Lindstrom P: A 24-hour continuous infusion study of bivalirudin in the rat. Int J Toxicol. 2003 May-Jun;22(3):195-206. [PubMed:12851152 ]
External Links
ATC CodesB01AE06
AHFS Codes
  • 20:12.04.12
PDB Entries
FDA labelDownload (60.4 KB)
MSDSNot Available
ADMET
Predicted ADMET featuresNot Available
Pharmacoeconomics
Manufacturers
  • The medicines co
Packagers
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionIntravenous250 mg/1
Powder, for solutionIntravenous250 mg
Prices
Unit descriptionCostUnit
Angiomax 250 mg vial780.0USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2065150 No1999-12-142010-08-17Canada
US5196404 No1993-05-232010-05-23Us
US7582727 Yes2009-01-272029-01-27Us
US7598343 Yes2009-01-272029-01-27Us
Properties
StateLiquid
Experimental Properties
PropertyValueSource
Predicted Properties
PropertyValueSource
Water Solubility0.0464 mg/mLALOGPS
logP-0.76ALOGPS
logP-14ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)2.79ChemAxon
pKa (Strongest Basic)11.88ChemAxon
Physiological Charge-4ChemAxon
Hydrogen Acceptor Count37ChemAxon
Hydrogen Donor Count28ChemAxon
Polar Surface Area901.57 Å2ChemAxon
Rotatable Bond Count66ChemAxon
Refractivity543.33 m3·mol-1ChemAxon
Polarizability215.46 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as polypeptides. These are peptides containing ten or more amino acid residues.
KingdomOrganic compounds
Super ClassOrganic Polymers
ClassPolypeptides
Sub ClassNot Available
Direct ParentPolypeptides
Alternative Parents
Substituents
  • Polypeptide
  • Alpha peptide
  • Hexacarboxylic acid or derivatives
  • N-acyl-aliphatic-alpha amino acid
  • N-acyl-alpha amino acid or derivatives
  • N-acyl-alpha-amino acid
  • Alpha-amino acid amide
  • N-acyl-l-alpha-amino acid
  • Phenylpropylamine
  • Amphetamine or derivatives
  • Alpha-amino acid or derivatives
  • N-substituted-alpha-amino acid
  • Pyrrolidine-2-carboxamide
  • Pyrrolidine carboxylic acid or derivatives
  • N-acylpyrrolidine
  • Aralkylamine
  • Phenol
  • Amino fatty acid
  • Fatty acyl
  • Benzenoid
  • N-acyl-amine
  • Fatty amide
  • Monocyclic benzene moiety
  • Tertiary carboxylic acid amide
  • Pyrrolidine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Primary carboxylic acid amide
  • Guanidine
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Carboximidamide
  • Carboxylic acid
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Primary aliphatic amine
  • Imine
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Thrombospondin receptor activity
Specific Function:
Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing.
Gene Name:
F2
Uniprot ID:
P00734
Molecular Weight:
70036.295 Da
References
  1. Scatena R: Bivalirudin: a new generation antithrombotic drug. Expert Opin Investig Drugs. 2000 May;9(5):1119-27. [PubMed:11060732 ]
  2. Bates ER: Bivalirudin for percutaneous coronary intervention and in acute coronary syndromes. Curr Cardiol Rep. 2001 Sep;3(5):348-54. [PubMed:11504570 ]
  3. Gladwell TD: Bivalirudin: a direct thrombin inhibitor. Clin Ther. 2002 Jan;24(1):38-58. [PubMed:11833835 ]
  4. Kleiman NS, Klem J, Fernandes LS, Rubin H, Challa S, Solomon S, Maresh K, Arora U, Klem E, Buergler J, Mathew S, Browning A, DeLao T: Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide. Am Heart J. 2002 Apr;143(4):585-93. [PubMed:11923794 ]
  5. Carswell CI, Plosker GL: Bivalirudin: a review of its potential place in the management of acute coronary syndromes. Drugs. 2002;62(5):841-70. [PubMed:11929334 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Peroxidase activity
Specific Function:
Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity.
Gene Name:
MPO
Uniprot ID:
P05164
Molecular Weight:
83867.71 Da
References
  1. Rudolph V, Rudolph TK, Schopfer FJ, Bonacci G, Lau D, Szocs K, Klinke A, Meinertz T, Freeman BA, Baldus S: Bivalirudin decreases NO bioavailability by vascular immobilization of myeloperoxidase. J Pharmacol Exp Ther. 2008 Nov;327(2):324-31. doi: 10.1124/jpet.108.142414. Epub 2008 Aug 13. [PubMed:18701766 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 07, 2016 03:54